• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Advertisement

Hyderabad Feb. 8 Jupiter Biosciences Ltd (JBL) has received a big order from the Swiss Bachem AG, a global leader of peptides. The business relationship is expected to be of a long-term nature.

JBL, a peptide-pharmaceuticals company, has also entered into confidentiality agreements with a big pharma company in Europe and in India for potential business collaborations in the peptide and chiral chemistry areas.

In a notification to the stock exchanges, the Chairman and Managing Director, Mr Venkat R. Kalavakolanu, said the company has also received commitment from a Nasdaq-listed company in the US for a sizeable amount of business related to peptides.

Mr Rudolf Tanner, a former Senior Vice-President of Bachem, had joined the board of JBL in 2005. Bachem, with estimated turnover of $175 million, is a leading player in the peptide business.

JBL is planning to set up a manufacturing base in Maryland, US, for peptide-related products. It is also looking at Japan for expanding its business opportunities. It has recently decided to raise funds through the FCCB route for its growth.

More Stories on : New Business | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Sandvik Asia to set up new R&D centre in Pune

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line